Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HH2853 Phase 1b/2 Study in Relapsed/Refractory Peripheral T-cell Lymphoma
jRCT2031230059Phase 2Active, not recruiting
- Sponsor
- Haihe
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of HH2853 in peripheral T-cell lymphoma (PTCL) and non-Hodgkin lymphoma (NHL), sponsored by Haihe. Primary endpoint: ORR. Started Apr 2023; status: active, not recruiting.
02
Drugs
HH2853
03
Conditions
peripheral T-cell lymphoma (PTCL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on jRCT2031230059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230059.